Negative correlation of high serum bilirubin with cancer development in adults without hepatobiliary disease.
Journal
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
ISSN: 1473-5709
Titre abrégé: Eur J Cancer Prev
Pays: England
ID NLM: 9300837
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
pubmed:
22
10
2020
medline:
15
12
2021
entrez:
21
10
2020
Statut:
ppublish
Résumé
This study aimed to evaluate whether serum bilirubin levels were associated with cancer development in a population without liver disease. A retrospective longitudinal study was performed by including participants who underwent a health checkup at St. Luke's International Hospital in Tokyo from 2005 to 2019. We excluded those with liver diseases or prior history of cancer at baseline. All participants were classified into four groups according to their total bilirubin (T-Bil) level: very low (<0.5 mg/dl), low (≥0.5 mg/dl, <1.0 mg/dl), intermediate (≥1.0 mg/dl, <1.5 mg/dl), and high (≥1.5 mg/dl). Our primary outcome was to observe cancer development. This study received IRB approval (19-R041). A total of 77 855 patients were included. During a median follow-up of 1751 days, 5110 participants developed some type of cancer during the study period. Compared to the very-low group, odds ratio (OR) for developing any type of cancer in a concentration-dependent manner decreased as the T-Bil category shifted to higher groups: OR 0.89, 95% confidence interval (CI) 0.79-1.01 for low group; OR 0.81, 95% CI 0.71-0.94 for intermediate group, and OR 0.80, 95% CI 0.65-0.99 for high group. In terms of secondary outcome, neoplasms of the female genital organs showed the same trend; OR 0.69, 95% CI 0.51-0.93 for low group; OR 0.63, 95% CI 0.44-0.92 for intermediate group, and OR 0.52, 95% CI 0.24-1.09 for high group. Increased serum bilirubin negatively correlated with cancer development in a concentration-dependent manner, especially for neoplasms of the female genital organs.
Sections du résumé
BACKGROUND AND AIMS
This study aimed to evaluate whether serum bilirubin levels were associated with cancer development in a population without liver disease.
METHODS
A retrospective longitudinal study was performed by including participants who underwent a health checkup at St. Luke's International Hospital in Tokyo from 2005 to 2019. We excluded those with liver diseases or prior history of cancer at baseline. All participants were classified into four groups according to their total bilirubin (T-Bil) level: very low (<0.5 mg/dl), low (≥0.5 mg/dl, <1.0 mg/dl), intermediate (≥1.0 mg/dl, <1.5 mg/dl), and high (≥1.5 mg/dl). Our primary outcome was to observe cancer development. This study received IRB approval (19-R041).
RESULTS
A total of 77 855 patients were included. During a median follow-up of 1751 days, 5110 participants developed some type of cancer during the study period. Compared to the very-low group, odds ratio (OR) for developing any type of cancer in a concentration-dependent manner decreased as the T-Bil category shifted to higher groups: OR 0.89, 95% confidence interval (CI) 0.79-1.01 for low group; OR 0.81, 95% CI 0.71-0.94 for intermediate group, and OR 0.80, 95% CI 0.65-0.99 for high group. In terms of secondary outcome, neoplasms of the female genital organs showed the same trend; OR 0.69, 95% CI 0.51-0.93 for low group; OR 0.63, 95% CI 0.44-0.92 for intermediate group, and OR 0.52, 95% CI 0.24-1.09 for high group.
CONCLUSION
Increased serum bilirubin negatively correlated with cancer development in a concentration-dependent manner, especially for neoplasms of the female genital organs.
Identifiants
pubmed: 33086248
doi: 10.1097/CEJ.0000000000000643
pii: 00008469-202101000-00008
doi:
Substances chimiques
Bilirubin
RFM9X3LJ49
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
69-75Références
Adachi Y, Nanno T, Yamamoto T. [Japanese clinical statistical data of patients with constitutional jaundice]. Nihon Rinsho. 1992; 50Suppl677–685
Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, et al.; Women’s Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA. 2003; 290:1739–1748
Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N Engl J Med. 1995; 333:1171–1175
Brierley CH, Burchell B. Human UDP-glucuronosyl transferases: chemical defence, jaundice and gene therapy. Bioessays. 1993; 15:749–754
Bulmer AC, Verkade HJ, Wagner KH. Bilirubin and beyond: a review of lipid status in Gilbert’s syndrome and its relevance to cardiovascular disease protection. Prog Lipid Res. 2013; 52:193–205
Cao Y, Giovannucci EL. Alcohol as a risk factor for cancer. Semin Oncol Nurs. 2016; 32:325–331
Claridge LC, Armstrong MJ, Booth C, Gill PS. Gilbert’s syndrome. BMJ. 2011; 342:d2293
Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R; Collaborative Group On Epidemiological Studies Of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet. 2015; 385:1835–1842
Cordel E, Reix N, Molière S, Mathelin C. [Hyperthyroidism and breast cancer: Is there a link?]. Gynecol Obstet Fertil Senol. 2018; 46:403–413
Duguay Y, McGrath M, Lépine J, Gagné JF, Hankinson SE, Colditz GA, et al. The functional UGT1A1 promoter polymorphism decreases endometrial cancer risk. Cancer Res. 2004; 64:1202–1207
Erlinger S, Arias IM, Dhumeaux D. Inherited disorders of bilirubin transport and conjugation: new insights into molecular mechanisms and consequences. Gastroenterology. 2014; 146:1625–1638
Fang JL, Beland FA, Doerge DR, Wiener D, Guillemette C, Marques MM, Lazarus P. Characterization of benzo(a)pyrene-trans-7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes. Cancer Res. 2002; 62:1978–1986
Fang X, Wei J, He X, Lian J, Han D, An P, et al. Quantitative association between body mass index and the risk of cancer: a global meta-analysis of prospective cohort studies. Int J Cancer. 2018; 143:1595–1603
Frei B, Stocker R, Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci U S A. 1988; 85:9748–9752
Fretzayas A, Moustaki M, Liapi O, Karpathios T. Gilbert syndrome. Eur J Pediatr. 2012; 171:11–15
Gilbert A, Lereboullet P. La cholemie simple familiale. Sem Med. 1901; 21:241–248
Girard H, Thibaudeau J, Court MH, Fortier LC, Villeneuve L, Caron P, et al. UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. Hepatology. 2005; 42:448–457
Higuchi S, Kabeya Y, Uchida J, Kato K, Tsukada N. Low Bilirubin levels indicate a high risk of cerebral deep white matter lesions in apparently healthy subjects. Sci Rep. 2018; 8:6473
King D, Armstrong MJ. Overview of Gilbert’s syndrome. Drug Ther Bull. 2019; 57:27–31
Kwon YJ, Lee YJ, Park BJ, Hong KW, Jung DH. Total serum bilirubin and 8-year incident type 2 diabetes mellitus: the Korean Genome and Epidemiology Study. Diabetes Metab. 2018; 44:346–353
Liu YF, Chang HY, Su HH. Dubin-johnson syndrome with extrahepatic pigmentation in a neurofibroma. Report of a case. Chin Med J. 1965; 84:386–389
Black M, Billing BH. Hepatic bilirubin UDP-glucuronosyltransferase activity in liver disease and Gilbert’s syndrome. N Engl J Med. 1969; 280:1266–1271
Macacu A, Autier P, Boniol M, Boyle P. Active and passive smoking and risk of breast cancer: a meta-analysis. Breast Cancer Res Treat. 2015; 154:213–224
Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017; 1:CD004143
Mashitani T, Hayashino Y, Okamura S, Tsujii S, Ishii H. Correlations between serum bilirubin levels and diabetic nephropathy progression among Japanese type 2 diabetic patients: a prospective cohort study (diabetes distress and care registry at Tenri [DDCRT 5]). Diabetes Care. 2014; 37:252–258
McGrath M, Lepine J, Lee IM, Villeneuve L, Buring J, Guillemette C, De Vivo I. Genetic variations in UGT1A1 and UGT2B7 and endometrial cancer risk. Pharmacogenet Genomics. 2009; 19:239–243
Miao ZF, Xu H, Xu YY, Wang ZN, Zhao TT, Song YX, Xu HM. Diabetes mellitus and the risk of gastric cancer: a meta-analysis of cohort studies. Oncotarget. 2017; 8:44881–44892
Miyaoka T. [Schizophrenia and idiopathic unconjugated hyperbilirubinemia (Gilbert’s syndrome)]. Seishin Shinkeigaku Zasshi. 2011; 113:361–367
Nakamura S, Morioka S, Baba S, Maeda M, Muro H. [Massive hepatic resection for metastatic cancer associated with Dubin-Johnson syndrome. Report of a case]. Nihon Geka Gakkai Zasshi. 1983; 84:135–140
Neuzil J, Stocker R. Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Biol Chem. 1994; 269:16712–16719
Okamura J, Monden M, Horikawa S, Sikujara O, Kosaki G, Seki K, et al. Hepatocellular carcinoma in a case of Dubin-Johnson syndrome treated successfully with right extended lobectomy. Jpn J Surg. 1980; 10:343–347
Ollinger R, Kogler P, Troppmair J, Hermann M, Wurm M, Drasche A, et al. Bilirubin inhibits tumor cell growth via activation of ERK. Cell Cycle. 2007; 6:3078–3085
Ollinger R, Bilban M, Erat A, Froio A, McDaid J, Tyagi S, et al. Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation. Circulation. 2005; 112:1030–1039
Owens D, Evans J. Population studies on Gilbert’s syndrome. J Med Genet. 1975; 12:152–156
Palaniappan L, Garg A, Enas E, Lewis H, Bari S, Gulati M, et al. South Asian cardiovascular disease & cancer risk: genetics & pathophysiology. J Community Health. 2018; 43:1100–1114
Park S, Lee S, Kim Y, Lee Y, Kang MW, Han K, et al. Risk of cancer in pre-dialysis chronic kidney disease: a nationwide population-based study with a matched control group. Kidney Res Clin Pract. 2019; 38:60–70
Powell LW. Clinical aspects of unconjugated hyperbilirubinemia. Semin Hematol. 1972; 9:91–105
Radišauskas R, Kuzmickienė I, Milinavičienė E, Everatt R. Hypertension, serum lipids and cancer risk: a review of epidemiological evidence. Medicina (Kaunas). 2016; 52:89–98
Ribrag V, Koscielny S, Casasnovas O, Cazeneuve C, Brice P, Morschhauser F, et al.; Groupe d’Etude des Lymphomes agressifs group, Laboratoire de Génétique et de recherche translationnelle, and Institut Gustave Roussy. Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. Blood. 2009; 113:3307–3313
Rojas K, Stuckey A. Breast cancer epidemiology and risk factors. Clin Obstet Gynecol. 2016; 59:651–672
Sedlak TW, Snyder SH. Bilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle. Pediatrics. 2004; 113:1776–1782
Sillah A, Watson NF, Schwartz SM, Gozal D, Phipps AI. Sleep apnea and subsequent cancer incidence. Cancer Causes Control. 2018; 29:987–994
Sticova E, Jirsa M. New insights in bilirubin metabolism and their clinical implications. World J Gastroenterol. 2013; 19:6398–6407
Sticova E, Elleder M, Hulkova H, Luksan O, Sauer M, Wunschova-Moudra I, et al. Dubin-Johnson syndrome coinciding with colon cancer and atherosclerosis. World J Gastroenterol. 2013; 19:946–950
Stocker R, Glazer AN, Ames BN. Antioxidant activity of albumin-bound bilirubin. Proc Natl Acad Sci U S A. 1987a; 84:5918–5922
Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science. 1987b; 235:1043–1046
Stoeckius M, Erat A, Fujikawa T, Hiromura M, Koulova A, Otterbein L, et al. Essential roles of Raf/extracellular signal-regulated kinase/mitogen-activated protein kinase pathway, YY1, and Ca2+ influx in growth arrest of human vascular smooth muscle cells by bilirubin. J Biol Chem. 2012; 287:15418–15426
Stout NL, Baima J, Swisher AK, Winters-Stone KM, Welsh J. A systematic review of exercise systematic reviews in the cancer literature (2005-2017). PM R. 2017; 9:S347–S384
Strassburg CP. Pharmacogenetics of Gilbert’s syndrome. Pharma cogenomics. 2008; 9:703–715
Strassburg CP. Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome). Best Pract Res Clin Gastroenterol. 2010; 24:555–571
Sun LM, Liang JA, Lin CL, Lin MC, Chang NJ, Kao CH. Cancer risk in patients with osteoporosis: a population-based cohort study. Curr Med Res Opin. 2017; 33:733–739
Tang KS, Chiu HF, Chen HH, Eng HL, Tsai CJ, Teng HC, Huang CS. Link between colorectal cancer and polymorphisms in the uridine-diphosphoglucuronosyltransferase 1A7 and 1A1 genes. World J Gastroenterol. 2005; 11:3250–3254
Trabert B, Wentzensen N, Yang HP, Sherman ME, Hollenbeck AR, Park Y, Brinton LA. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int J Cancer. 2013; 132:417–426
Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol. 2000; 40:581–616
Usher-Smith JA, Walter FM, Emery JD, Win AK, Griffin SJ. Risk prediction models for colorectal cancer: a systematic review. Cancer Prev Res (Phila). 2016; 9:13–26
Vickers MR, MacLennan AH, Lawton B, Ford D, Martin J, Meredith SK, et al.; WISDOM group. Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ. 2007; 335:239
Vítek L, Jirsa M, Brodanová M, Kalab M, Marecek Z, Danzig V, et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis. 2002; 160:449–456
Yao L, Qiu LX, Yu L, Yang Z, Yu XJ, Zhong Y, et al. The association between TA-repeat polymorphism in the promoter region of UGT1A1 and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2010; 122:879–882
Zelenka J, Dvořák A, Alán L, Zadinová M, Haluzík M, Vítek L. Hyperbilirubinemia protects against aging-associated inflammation and metabolic deterioration. Oxid Med Cell Longev. 2016; 2016:6190609
Zhou J, Tracy TS, Remmel RP. Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors. Drug Metab Dispos. 2011; 39:322–329